Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer. Among patients with BRAF V600E-mutant metastatic ...
Please provide your email address to receive an email when new articles are posted on . In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback